⚕️ The information below is for educational purposes only. It is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
Infertility affects approximately 10–15% of Indian couples, and obesity is one of its most modifiable risk factors. GLP-1 medications — semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro) — are increasingly being prescribed to Indian patients with obesity and infertility, or to women with PCOS preparing for assisted reproductive technology (ART) such as IVF or IUI. This guide covers what every Indian patient needs to know before, during, and after fertility treatment on GLP-1 medications.
**Consult your healthcare provider before starting any medication. GLP-1 medications are contraindicated during pregnancy — stopping well before conception is essential.**
Excess body weight affects fertility through multiple mechanisms:
**The evidence base is clear:** A 5–10% reduction in body weight significantly improves spontaneous conception rates, IVF success rates, and miscarriage risk. This is where GLP-1 medications become relevant for Indian fertility patients.
PCOS (polycystic ovary syndrome) is the most common hormonal disorder in Indian women of reproductive age, affecting an estimated 1 in 5 Indian women. Its core driver is insulin resistance — which GLP-1 medications directly address.
Multiple Indian studies and global trials have shown that GLP-1 therapy in women with PCOS:
For Indian women with PCOS and obesity who have been trying to conceive, GLP-1 therapy followed by ovulation induction or IVF/IUI can be a structured pathway to pregnancy.
Obesity significantly reduces IVF success rates. A BMI above 30 is associated with:
**Weight loss of 5–10% before IVF meaningfully improves outcomes.** Many Indian IVF clinics — including Nova IVF, Manipal Fertility, Cloudnine, and government hospital ART centres — now recommend or require weight management before proceeding in patients with BMI above 30–35.
GLP-1 therapy in obese men improves:
A 2024 study in the Journal of Clinical Endocrinology and Metabolism showed that 16 weeks of semaglutide therapy in obese men with hypogonadism restored normal testosterone levels in over 70% of participants.
GLP-1 medications are **contraindicated in pregnancy.** Animal studies show foetal harm at high doses, and the medications cross the placental barrier. While human data is limited (because trials exclude pregnant women), no GLP-1 medication has established safety in human pregnancy.
**The current recommendation from CDSCO, the American Society for Reproductive Medicine (ASRM), and the ESHRE:**
**Why 2 months?** Semaglutide has a half-life of approximately 7 days. After stopping a weekly injection, the drug takes approximately 5–7 weeks to clear the body. A 2-month buffer ensures both drug clearance and at least one full menstrual cycle before conception.
Work with both your endocrinologist/obesity physician and your fertility specialist. Goals:
GLP-1 is stopped. Fertility treatment proceeds. Key dietary considerations:
GLP-1 medications are also contraindicated during breastfeeding. Resume GLP-1 therapy only after weaning, with guidance from your doctor. Postpartum weight retention is common, and GLP-1 therapy can be restarted when medically appropriate — typically 3–6 months after delivery and after weaning.
GLP-1 medications reduce appetite and food intake. In women preparing for conception, this creates additional risk for nutrient gaps that directly affect fertility:
| Nutrient | Why It Matters for Fertility | Indian Sources | Supplement? |
|----------|------------------------------|---------------|-------------|
| **Folate/Folic acid** | Neural tube defect prevention; DNA synthesis in eggs | Palak, methi, dal, eggs | Yes — 400–5,000 mcg/day |
| **Vitamin D** | Implantation success; PCOS androgen regulation | Sunlight, fortified milk, eggs | Usually yes — test first |
| **Iron** | Ovulation; embryo energy production | Rajma, spinach, red meat | If ferritin <30 |
| **Omega-3 fatty acids** | Egg quality; embryo development | Mackerel, sardines, flaxseed | Consider fish oil if diet low |
| **CoQ10** | Mitochondrial function in eggs (especially women 35+) | Meat, fish, nuts | Often recommended by fertility doctors |
| **Zinc** | Sperm production; egg maturation | Pumpkin seeds, meat, chickpeas | Check levels |
| **Iodine** | Thyroid function (critical in early pregnancy) | Iodised salt, dairy | Ensure iodised salt use |
IVF in India ranges from ₹80,000–2,50,000 per cycle depending on the clinic, city, and protocol. Most government hospitals offering ART services charge significantly less.
**Major IVF chains in India:** Nova IVF, Cloudnine, Manipal Fertility, Oasis Fertility, Birla Fertility, Apollo Fertility, AIIMS (government rates)
GLP-1 medications prescribed for fertility optimisation before IVF are rarely covered by insurance — but some corporate health insurance plans cover obesity management medications. Check your policy under "metabolic disorder management."
**Continuing GLP-1 into an IVF cycle.** This is the most serious error. Always confirm with both your fertility doctor and the prescribing physician that GLP-1 has been stopped at the appropriate time.
**Stopping GLP-1 and reverting to old eating habits.** The 3–9 months on GLP-1 should be used to establish sustainable dietary and exercise habits. The medication is a tool, not a permanent solution. Reverting to high-calorie eating after stopping will reverse metabolic gains before the IVF cycle.
**Not addressing thyroid function.** Hypothyroidism is extremely common in Indian women with PCOS (10–15% co-occurrence) and profoundly affects fertility. Ensure TSH is tested and optimised (target TSH <2.5 for fertility) before IVF.
**Underestimating the male factor.** In India, male infertility causes or contributes to 40–50% of infertility cases, yet male partners often resist evaluation. GLP-1 therapy can improve sperm parameters in obese men — ensure the male partner is evaluated and, if obese, considered for appropriate treatment.
Consult a fertility specialist (reproductive endocrinologist or reproductive medicine specialist) if:
A team approach — endocrinologist, fertility specialist, dietitian — gives the best outcomes.
**Can GLP-1 medications cause miscarriage?**
There are isolated case reports of miscarriage in patients who conceived while on GLP-1 medications, but it is not established whether the medication or the underlying condition (obesity, PCOS) was the cause. This is precisely why stopping 2+ months before conception is recommended — to eliminate any possible foetal exposure.
**I got pregnant unexpectedly while on GLP-1 — what should I do?**
Stop the medication immediately and contact your obstetrician or gynaecologist today. Do not panic — the absolute risk from brief early exposure is not clearly defined, but the drug should be stopped at once. Your doctor will advise on monitoring.
**Does weight loss from GLP-1 permanently improve PCOS?**
GLP-1-driven weight loss improves PCOS symptoms while weight is maintained. Sustained weight management after stopping GLP-1 maintains these benefits. Regaining the weight reverses the improvements — making long-term lifestyle change, not just the medication period, the critical factor.
**My IVF doctor says I need to lose 10 kg before they'll proceed — how quickly can I do this on GLP-1?**
At typical GLP-1 response rates (0.5–1 kg per week), losing 10 kg takes 10–20 weeks. Many patients achieve this in 3–5 months on GLP-1 combined with dietary changes. Allow an additional 2 months after stopping for drug clearance, meaning the total timeline from starting GLP-1 to IVF is approximately 5–7 months. This is worth planning carefully with your fertility team.
